Health claims in the labelling and marketing of food products:: the Swedish food sector's Code of Practice in a European perspective

Since 1990 certain health claims in the labelling and marketing of food products have been allowed in Sweden within the food sector's Code of Practice. The rules were developed in close dialogue with the authorities. The legal basis was a decision by the authorities not to apply the medicinal products’ legislation to “foods normally found on the dinner table” provided the rules defined in the Code were followed. The Code of Practice lists nine well-established diet–health relationships eligible for generic disease risk reduction claims in two steps and general rules regarding nutrient function claims. Since 2001, there has also been the possibility for using “product-specific physiological claims (PFP)”, subject to premarketing evaluation of the scientific dossier supporting the claim. The scientific documentation has been approved for 10 products with PFP, and another 15 products have been found to fulfil the Code's criteria for “low glycaemic index”. In the third edition of the Code, active since 2004, conditions in terms of nutritional composition were set, i.e. “nutrient profiles”, with a general reference to the Swedish National Food Administration's regulation on the use of a particular symbol, i.e. the keyhole symbol. Applying the Swedish Code of practice has provided experience useful in the implementation of the European Regulation on nutrition and health claims made on foods, effective from 2007

The HMG-I/Y-related protein p8 binds to p300 and Pax2 trans-activation domain-interacting protein to regulate the trans-activation activity of the Pax2A and Pax2B transcription factors on the glucagon gene promoter

p8 is a nuclear DNA-binding protein, which was identified because its expression is strongly activated in response to several stresses. Biochemical and biophysical studies revealed that despite a weak sequence homology p8 is an HMG-I/Y-like protein, suggesting that p8 may be involved in transcription regulation. Results reported here strongly support this hypothesis. Using a pull-down approach, we found that p8 interacts with the general co-activator p300. We also found that, similar to the HMG proteins, p300 was able to acetylate recombinant p8 in vitro, although the significance of such modification remains to be determined. Then a screening by the two-hybrid system, using p8 as bait, allowed us to identify the Pax2 trans-activation domain-interacting protein (PTIP) as another partner of p8. Transient transfection studies revealed that PTIP is a strong inhibitor of the trans-activation activities of Pax2A and Pax2B on the glucagon gene promoter, which was chosen as a model because it is a target of the Pax2A and Pax2B transcription factors. This effect is completely abolished by co-transfection of p8 in glucagon-producing InRIG9 cells, indicating that p8 binding to PTIP prevents inhibition of the glucagon gene promoter. This was not observed in NIH3T3 fibroblasts that do not express glucagon. Finally, expression of p8 enhances the effect of p300 on Pax2A and Pax2B trans-activation of the glucagon gene promoter. These observations suggest that in glucagon-producing cells p8 is a positive cofactor of the activation of the glucagon gene promoter by Pax2A and Pax2B, both by recruiting the p300 cofactor to increase the Pax2A and Pax2B activities and by binding the Pax2-interacting protein PTIP to suppress its inhibition.Fil:Mallo, G.V. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina.Fil:Moreno, S. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales; Argentina

Investigation of interaction femtosecond laser pulses with skin and eyes mathematical model

We present a mathematical model of linear and nonlinear processes that takes place under the action of femtosecond laser radiation on the cutaneous covering. The study is carried out and the analytical solution of the set of equations describing the dynamics of the electron and atomic subsystems and investigated the processes of linear and nonlinear interaction of femtosecond laser pulses in the vitreous of the human eye, revealed the dependence of the pulse duration on the retina of the duration of the input pulse and found the value of the radiation power density, in which there is a self-focusing is obtained. The results of the work can be used to determine the maximum acceptable energy, generated by femtosecond laser systems, and to develop Russian laser safety standards for femtosecond laser systems

Technoeconomic and life-cycle analysis of single-step catalytic conversion of wet ethanol into fungible fuel blendstocks

Technoeconomic and life-cycle analyses are presented for catalytic conversion of ethanol to fungible hydrocarbon fuel blendstocks, informed by advances in catalyst and process development. Whereas prior work toward this end focused on 3-step processes featuring dehydration, oligomerization, and hydrogenation, the consolidated alcohol dehydration and oligomerization (CADO) approach described here results in 1-step conversion of wet ethanol vapor (40 wt% in water) to hydrocarbons and water over a metal-modified zeolite catalyst. A development project increased liquid hydrocarbon yields from 36% of theoretical to >80%, reduced catalyst cost by an order of magnitude, scaled up the process by 300-fold, and reduced projected costs of ethanol conversion 12-fold. Current CADO products conform most closely to gasoline blendstocks, but can be blended with jet fuel at low levels today, and could potentially be blended at higher levels in the future. Operating plus annualized capital costs for conversion of wet ethanol to fungible blendstocks are estimated at $2.00/GJ for CADO today and$1.44/GJ in the future, similar to the unit energy cost of producing anhydrous ethanol from wet ethanol ($1.46/GJ). Including the cost of ethanol from either corn or future cellulosic biomass but not production incentives, projected minimum selling prices for fungible blendstocks produced via CADO are competitive with conventional jet fuel when oil is$100 per barrel but not at $60 per barrel. However, with existing production incentives, the projected minimum blendstock selling price is competitive with oil at$60 per barrel. Life-cycle greenhouse gas emission reductions for CADO-derived hydrocarbon blendstocks closely follow those for the ethanol feedstock

Evaluating of HPV-DNA ISH as an adjunct to p16 testing in oropharyngeal cancer

© 2020 Jeffrey Chi. Aim: Current guidelines recommend p16 immunohistochemistry (IHC) for testing human papillomavirus (HPV) in oropharyngeal carcinoma (OPSCC). We evaluated the value of adding DNA in situ hybridization (ISH) to p16 IHC. Methods: Fifty patients with OPSCC were analyzed. Concordance between HPV-DNA ISH and p16 IHC was measured by Gwet\u27s agreement coefficient. Results: p16 IHC was positive in 35/48 (72.9%), negative in 8/48 (16.7%) patients. Wide spectrum DNA-ISH was positive in 9/23 (39%) and negative in 14/23 (60.9%) patients. High-risk 16/18 (HR) HPV DNA-ISH was positive in 11/23 (47.8%) and negative in 12 (52.2%) patients. The agreement between HPV DNA-ISH and p16 IHC is fair (Gwet\u27s AC1 = 0.318). Conclusion: The agreement between p16 IHC and HPV-DNA ISH was fair. However, ISH sensitivity was low. Our findings add to the current data that p16 IHC testing is reliable and may be enough as a stand-alone test for HPV detection in OPSCC. Current testing guidelines recommend p16 immunochemistry (IHC) for detecting human papillomavirus (HPV) in oropharyngeal cancer (OPSCC). We evaluated the value of adding HPV DNA in situ hybridization (ISH) to p16 IHC. Fifty patients with OPSCC were analyzed. p16 IHC was positive in 72.9% of patients and DNA-ISH was positive in 39% of patients when wide spectrum probe was used and positive in 47.8% of patients when high-risk probe was used. The agreement between the two tests was fair. However, DNA-ISH sensitivity was low. p16 IHC may be enough as a stand-alone test for detection of HPV in OPSCC

Autoantibodies against NMDAR subunit NR1 disappear from blood upon anesthesia

Anesthetics penetrate the blood-brain-barrier (BBB) and - as confirmed preclinically – transiently disrupt it. An analogous consequence in humans has remained unproven. In mice, we previously reported that upon BBB dysfunction, the brain acts as ‘immunoprecipitator’ of autoantibodies against N-methyl-D-aspartate-receptor subunit-NR1 (NMDAR1-AB). We thus hypothesized that during human anesthesia, pre-existing NMDAR1-AB will specifically bind to brain. Screening of N = 270 subjects undergoing general anesthesia during cardiac surgery for serum NMDAR1-AB revealed N = 25 NMDAR1-AB seropositives. Only N = 14 remained positive post-surgery. No changes in albumin, thyroglobulin or CRP were associated with reduction of serum NMDAR1-AB. Thus, upon anesthesia, BBB opening likely occurs also in humans

Robust paths to net greenhouse gas mitigation and negative emissions via advanced biofuels

ACKNOWLEDGEMENTS We thank Dennis Ojima and Daniel L. Sanchez for their encouragement on this topic. The authors gratefully acknowledge partial support as follows: J.L.F., L.R.L., T.L.R., E.A.H.S., and J.J.S., the Sao Paulo Research Foundation (FAPESP grant# 2014/26767-9); J.L.F., L.R.L., K.P., and T.L.R., The Center for Bioenergy Innovation, a U.S. Department of Energy Research Center supported by the Office of Biological and Environmental Research in the DOE Office of Science (grant# DE-AC05-00OR22725); L.R.L., the Sao Paulo Research Foundation, and the Link Foundation; J.L.F. and K.P., USDA/NIFA (grant# 2013-68005-21298 and 2017-67019-26327); T.L.R., USDA/NIFA (grant# 2012-68005-19703); D.S.L. and S.P.L., the Energy Biosciences Institute. Data availability The DayCent model (https://www2.nrel.colostate.edu/projects/daycent/) is freely available upon request. Specification of DayCent model runs and automated model initialization, calibration, scenario simulation, results analysis, and figure generation were implemented in Python 2.7, using the numpy module for data processing and the matplotlib module for figure generation. Analysis code is available in a version-controlled repository (https://github.com/johnlfield/Ecosystem_dynamics). A working copy of the code, all associated DayCent model inputs, and analysis outputs are also available in an online data repository (https://figshare.com/s/4c14ec168bd550db4bad; note this URL is for accessing a private version of the repository, and will eventually be replaced with an updated URL for the public version of the repository, which will only be accessible after the journal-specified embargo date).Peer reviewedPostprintPublisher PD

The new EC Regulation on nutrition and health claims on foods

The area of health claims has been unregulated in Europe until recently. A new regulation on nutrition and health claims made on foods came into force on 19 January 2007. The Regulation has been eagerly awaited by all parties involved. The Regulation includes 37 whereas clauses, 29 Articles and an annex for nutrition claims and conditions applying to them. In practice, three main types of health claim are included in the Regulation, as referred to in Articles 13 and 14. The type of the scientific evidence is described slightly differently for Article 13.1 and Article 13.5: “generally accepted scientific evidence” and “newly developed scientific evidence”, respectively, although the scientific status of evidence shall be the same for all kinds of claims. So far, there are four types of guidance for applying the Regulation. The wording of health claims is an essential issue in the Regulation, as well as the concept of nutrient profiles. In the Regulation there are three issues of special interest, when compared to the Swedish Food Sector's Code of Practice, i.e. concerns about “other substances”, “food supplements” and “the average consumer”. The Regulation will be evaluated in 2013, reporting the impact of this Regulation on dietary choices and the potential impact on obesity and non-communicable diseases